118 filings
Page 5 of 6
8-K
i16n0qsetvop
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
8-K
8ql 8efg1cxkdr
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
n3ru7lvyq8ac h99
8 May 18
Zafgen Reports First Quarter 2018 Operating and Financial Results
4:09pm
8-K
513 zdoha4qp6pjjr62v
6 Mar 18
Results of Operations and Financial Condition
12:00am
8-K
si2grtqhyuc5c3ppkxlm
5 Jan 18
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018
12:00am
8-K
j9awtsv kjpw
7 Nov 17
Zafgen Reports Third Quarter 2017 Financial Results
12:00am
8-K
c540gox
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
8-K
iqypn1n 8uggf
8 Aug 17
Zafgen Reports Second Quarter 2017 Financial Results
12:00am
8-K
6zorj qsbx22t9qfxhk
23 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
uxj7mx1u3w3ux
9 May 17
Zafgen Reports First Quarter 2017 Financial Results
12:00am
8-K
v5xj61hb wskf
4 May 17
Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
12:00am
8-K
os3go2z
9 Mar 17
Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K
hcz q9p402kozoufc3i5
9 Nov 16
Zafgen Reports Third Quarter 2016 Financial Results
12:00am
8-K
ecyc4u437 o18z2b6c
4 Aug 16
Zafgen Reports Second Quarter 2016 Financial Results
12:00am
8-K
36fc5hbp7 5f7urjmf3p
19 Jul 16
Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
12:00am
8-K
0e8sbp1mr28c
1 Jul 16
Departure of Directors or Certain Officers
12:00am
8-K
muwtltdm4zwv1apy1ze
10 May 16
Zafgen Reports First Quarter 2016 Financial Results
12:00am
8-K
2ri8khwu
9 Mar 16
Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results
12:00am
8-K
oaeixpheswdnl98le
8 Mar 16
Zafgen Adds Thomas O. Daniel, M.D. to its Board of Directors
12:00am
8-K
81lenvb13i160psq
18 Feb 16
Zafgen’s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves
12:00am